Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 4Recurrence 3Neuroblastoma 3Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Primary Myelofibrosis 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Neutrophilic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Fenretinide × Clear all
NCT01553071 2022-03-31

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

South Plains Oncology Consortium

Phase 1 Terminated
16 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡